Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Helios Underwriting

    MCap

    GBP179m

    Last close

    GBP2.46

    ▲ 27.00 (12.33%)

    Quadrise

    MCap

    GBP64m

    Last close

    GBP0.04

    ▲ 0.30 (9.09%)

    Actinogen Medical

    MCap

    AUD90m

    Last close

    AUD0.03

    ▲ 0.00 (7.41%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Immix Biopharma (NASDAQ: IMMX)

Last close As at 02/12/2024

USD2.01

▲ −0.10 (−4.74%)

Market capitalisation

USD56m

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Latest Insights

View More

Healthcare | Flash note

Immix Biopharma — US CAR-T trial progresses to dose expansion

Healthcare | Update

Immix Biopharma — Full steam ahead with US CAR-T trial

Healthcare | Flash note

Immix Biopharma — US$8m grant to advance novel CAR-T treatment

Healthcare | Flash note

Immix Biopharma — US CAR-T trial commences patient dosing
Scientist using protective robber gloves for handling substances and experiments
Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Ilya Rachman

    CEO

  • Gabriel Morris

    CFO

Cancer cells low poly blue

Flash note

Healthcare

Immix Biopharma — KOL event: Glimmer of hope for ALA patients

Flash note

Healthcare

Immix Biopharma — CAR-T trial moves to US with outpatient potential

Update

Healthcare

Immix Biopharma — A quarter of progress for both lead assets

Update

Healthcare

Immix Biopharma — A step toward delivering a practical CAR-T option

Flash note

Healthcare

Immix Biopharma — NXC-201 gains orphan drug designation in ALA

Flash note

Healthcare

Immix Biopharma — NXC-201 gains Orphan Drug designation in MM

Update

Healthcare

Immix Biopharma — Progressing as expected on all fronts
Cancer cells low poly blue

Flash note

Healthcare

Immix Biopharma — IMX-110 interim results in colorectal cancer

Flash note

Healthcare

Immix Biopharma — ATM completion may extend runway into H224

Update

Healthcare

Immix Biopharma — A quarter focusing on a CAR-T strategy

Flash note

Healthcare

Immix Biopharma — CAR-T treatment continues to show promise
Cancer cells low poly blue

Update

Healthcare

Immix Biopharma — Pipeline momentum continues in FY23
Scientist using protective robber gloves for handling substances and experiments

Flash note

Healthcare

Immix Biopharma — Positive data from CAR-T treatment continues
Scientist using protective robber gloves for handling substances and experiments

Update

Healthcare

Immix Biopharma — Expanding portfolio into CAR-T cell therapy
Scientist using protective robber gloves for handling substances and experiments

Flash note

Healthcare

Immix Biopharma — Encouraging progress on multiple fronts

Flash note

Healthcare

Immix Biopharma — Potential upside with expansion into CAR-T

Update

Healthcare

Immix Biopharma — IMX-110 clinical expansion on the horizon

edison tv

Healthcare

Immix Biopharma – executive interview

Initiation

Immix Biopharma — Fresh faces with a unique tissue-targeting therapy